26 febrero 2015
About 15 percent of people with pancreatic cancer may benefit from therapy targeting a newly identified gene signature, scientists say. This sub-group of pancreatic cancer patients who possess a strong angiogenic gene signature could benefit from personalized therapies that cut off the pathways that feed the cancer’s growth, they note.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/HpCBZnQaFbQ/150226101637.htm
